About Ovid Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://ovidrx.com/
Frequently Asked Questions
What is the 52-week range for OVID?
The 52-week high is $3.105 and the 52-week low is $1.18.
What is the P/E ratio for OVID?
The P/E ratio data is currently unavailable.
What is the dividend yield for OVID?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -23.64%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1105.75%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.89.
Analyst Recommendation Trends
Wall Street analyst consensus for OVID over the last few months:
Latest OVID News
What's going on in today's after hours session
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. futures mixed as Vail Resorts fell after a Q4 loss miss despite beating sales estimates; several stocks also declined premarket.
Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two
On August 13, Ovid Therapeutics (NASDAQ:OVID) reported financial results for the second quarter ended June 30, alongside a batch of pipeline updates. The biopharmaceutical company, which focuses on treatments for brain disorders, used the update to lay out progress on two clinical programs, a leadership shakeup, and a deal that hands off one of its […]
HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $5
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and raises the price target from $4 to $5.
Ovid Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company’s management will participate in two upcoming investor conferences: Cantor Global Healthcare Conference – Wednesday, September 9 at 2:10 pm ETH.C. Wainwright 28th Annual Global Investment Conference – Monday, September 14 at 11:30 am ET Webcasts of the pre
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-06 | Carter Charles Ross | +50,000 | - | - |
| 2026-06-15 | Greka Anna | +130,000 | - | - |
| 2026-04-07 | Fitzgerald Kevin Joseph | +17,578 | $2.56 | $45,000 |
| 2026-04-07 | Friedman Bart | +8,789 | $2.56 | $22,500 |
| 2026-04-07 | PAPADOPOULOS STELIOS | +17,578 | $2.56 | $45,000 |
| 2026-03-23 | LEVIN JEREMY M | -47,333 | - | - |
| 2026-03-23 | LEVIN JEREMY M | +47,333 | $1.4 | $66,266 |
| 2026-02-26 | ALEXANDER MARGARET A. | +1,435,000 | - | - |
| 2026-02-26 | Fitzgerald Kevin Joseph | +65,000 | - | - |
| 2026-02-26 | Bernstein Karen | +65,000 | - | - |
| 2026-02-26 | Friedman Bart | +65,000 | - | - |
| 2026-02-26 | DUNCAN BARBARA GAYLE | +65,000 | - | - |
| 2026-02-26 | Rona Jeffrey A | +408,750 | - | - |
| 2026-02-26 | Rona Jeffrey A | +68,125 | - | - |
| 2026-02-26 | LEVIN JEREMY M | +957,000 | - | - |
| 2026-02-26 | PAPADOPOULOS STELIOS | +65,000 | - | - |
| 2026-02-23 | ALEXANDER MARGARET A. | -11,656 | $1.45 | $16,901 |
| 2026-02-23 | Rona Jeffrey A | -8,541 | $1.45 | $12,384 |
| 2026-01-04 | ALEXANDER MARGARET A. | +890,000 | - | - |
| 2025-12-15 | LEVIN JEREMY M | -71 | - | - |
| 2025-12-15 | LEVIN JEREMY M | +71,000 | - | - |
| 2025-12-11 | LEVIN JEREMY M | +35,500 | - | - |
| 2025-12-11 | LEVIN JEREMY M | +47,333 | - | - |
| 2025-12-11 | LEVIN JEREMY M | +71 | - | - |
| 2025-12-08 | TAKEDA PHARMACEUTICAL CO LTD | -1,250 | - | - |
| 2025-12-08 | TAKEDA PHARMACEUTICAL CO LTD | +1,250,000 | - | - |